Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The 56 Point TA; Charts With an Attitude -- Ignore unavailable to you. Want to Upgrade?

To: David Graham who wrote (8032)	11/20/1997 3:45:00 PM
From: majormember	Respond to of 79450

Grammy, Damn ubonics got me talkin crazy, saying things that aint true, an meenin things that are. I have the same problem with the wife, ya'no. I'll tell her to try out those clothes at the C-Mart. Next thing ya know she has them up at the register like I was gonna buy them. Boy, how she went from "try" to "buy" really gets me, if ya no what ah mean. You, my dear Grammy, rightfully wants their news givin to them in a precise and accurate fashion. See if this sheds more light. BBI Newsletter Biomedical Business Internation COPYRIGHT BY Biomedical Business International SUNRISE TECHNOLOGIES has received approval from the Japanese Ministry of Health and Welfare to sell its gLASE 210 laser for treating glaucoma in Japan. Japan's nearly 10,000 ophthalmologists represent 25% of the world market for ophthalmic equipment. The gLASE 210 was the first holmium laser approved by the U.S. FDA (December 1990) for ophthalmic applications. It is used on outpatients to perform thermal laser sclerostomy, which releives the build-up of intraocular associated with glaucoma. Sorry for the ommision of "trail" in approval. Hope this cleers it up. <<gg>>x2 Skane